JSPR
Jasper Therapeutics Inc
NASDAQ: JSPR · HEALTHCARE · BIOTECHNOLOGY
$0.54
+3.84% today
Updated 2026-10-28
Market cap
$16.97M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.04
Dividend yield
—
52W range
$0 – $3
Volume
0.4M
WallStSmart proprietary scores
19
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C4.5
Quality
C3.0
Profitability
D5.0
Valuation
C+1/9
Piotroski F-Score
Weak
-18.6
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →272 stocks currently score above 75
Price targets
Analyst target
$20.00
+3611.95%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.19x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -18.58 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-6.92M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $13.51M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-37.69M | $-64.47M | $-71.27M | $-75.80M | $-2.76M |
| EPS | — | — | — | — | $-1.04 |
| Free cash flow | $-46.43M | $-52.33M | $-63.15M | $-77.17M | $-6.92M |
| Profit margin | -278.92% | — | — | — | — |
Peer comparison
Smart narrative
Jasper Therapeutics Inc trades at $0.54. Our Smart Value Score of 19/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -18.58, it sits in the distress.
Frequently asked questions
What is Jasper Therapeutics Inc's stock price?
Jasper Therapeutics Inc (JSPR) trades at $0.54.
Is Jasper Therapeutics Inc overvalued?
Jasper Therapeutics Inc carries a Smart Value Score of 19/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Jasper Therapeutics Inc (JSPR)?
The 12-month analyst consensus target is $20.00, about 3612.0% above the current $0.54. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Jasper Therapeutics Inc's Altman Z-Score is -18.58, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-244.20%
Beta3.04
50D MA$0.63
200D MA$0.88
Shares out0.03B
Float0.03B
Short ratio—
Avg volume0.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—